Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Assets (2022 - 2025)

Entrada Therapeutics has reported Current Assets over the past 4 years, most recently at $306.3 million for Q4 2025.

  • Quarterly results put Current Assets at $306.3 million for Q4 2025, down 30.4% from a year ago — trailing twelve months through Dec 2025 was $306.3 million (down 30.4% YoY), and the annual figure for FY2025 was $306.3 million, down 30.4%.
  • Current Assets for Q4 2025 was $306.3 million at Entrada Therapeutics, down from $338.3 million in the prior quarter.
  • Over the last five years, Current Assets for TRDA hit a ceiling of $489.5 million in Q2 2024 and a floor of $209.9 million in Q4 2022.
  • Median Current Assets over the past 4 years was $376.4 million (2023), compared with a mean of $360.9 million.
  • Biggest five-year swings in Current Assets: skyrocketed 76.19% in 2023 and later plummeted 30.4% in 2025.
  • Entrada Therapeutics' Current Assets stood at $209.9 million in 2022, then skyrocketed by 76.19% to $369.8 million in 2023, then grew by 19.0% to $440.0 million in 2024, then plummeted by 30.4% to $306.3 million in 2025.
  • The last three reported values for Current Assets were $306.3 million (Q4 2025), $338.3 million (Q3 2025), and $369.1 million (Q2 2025) per Business Quant data.